KU-60019
目录号:S1570 Purity: 99.69%
KU-60019是一种改进的KU-55933类似物,在无细胞试验中作用于ATM,IC50为6.3 nM,作用于ATM比作用于DNA-PK和ATR的选择性分别高270和1600倍,并且是高度有效的放射增敏剂。
CAS: 925701-49-1
客户使用Selleck的KU-60019发表文献141篇
- Nat Biomed Eng, 2024 10.1038/s41551-024-01273-9
- Nature, 2023 616(7955):168-175
- Cancer Cell, 2021 39-9:1214-1226.e10
- Nature, 2020 10.1038/s41586-020-2959-4
- Sci Immunol, 2020 5(43)
- Cell, 2019 176(3):505-519
- Mol Cancer, 2019 18(1):11
- Cancer Discov, 2018 8(1):74-93
- Nat Biotechnol, 2017 35(5):463-474
- Nat Cell Biol, 2016 18(11):1196-1207
- Nat Cell Biol, 2016 18(12):1357-1366
- Cell, 2013 21;155(5):1088-103.
- Nat Commun, 2024 15(1):5727
- Cell Death Dis, 2024 15(7):519
- Cell Rep, 2024 43(5):114205
- Elife, 2024 12RP91304
- Mol Biol Cell, 2024 35(8):br15
- bioRxiv, 2024 2024.06.24.600514
- Adv Sci (Weinh), 2023 10(28):e2206931
- Nucleic Acids Res, 2023 51(20):10970-10991
- Blood Cancer J, 2023 13(1):42
- Cancer Res, 2023 83(1):141-157
- Int J Biol Sci, 2023 19(3):981-993
- Cell Death Dis, 2023 14(9):622
- Commun Biol, 2023 6(1):249
- iScience, 2023 26(7):107090
- J Biol Chem, 2023 10.1016/j.jbc.2023.105385
- Mol Cells, 2023 46(8):486-495
- Biomol Ther (Seoul), 2023 31(5):559-565
- Cell Rep Methods, 2023 3(10):100599
- Nat Struct Mol Biol, 2022 29(7):639-652
- J Exp Med, 2022 219-12e20220541
- Cancer Res, 2022 82-18:3345-3358
- Cell Rep, 2022 38(2):110216
- Cell Rep, 2022 41(12):111826
- EMBO Rep, 2022 23(2):e53658
- Cell Biosci, 2022 12(1):43
- Breast Cancer Res, 2022 24(1):41
- J Virol, 2022 96(13):e0071422
- Am J Cancer Res, 2022 12(5):2363-2375
- Clin Proteomics, 2022 19(1):48
- PLoS One, 2022 17(8):e0271905
- Microbiol Spectr, 2022 e0188121
- Front Cardiovasc Med, 2022 9:942251
- Nat Commun, 2021 12(1):476
- Nat Commun, 2021 12(1):2529
- Autophagy, 2021 10.1080/15548627.2021.1936932
- Cell Death Differ, 2021 10.1038/s41418-020-00733-4
- Theranostics, 2021 11(4):1795-1813
- Cancer Res, 2021 81(18):4676-4684
- Cell Rep, 2021 37(8):110038
- Cell Rep, 2021 35(10):109220
- Cell Rep, 2021 37(2):109815
- Acta Pharmacol Sin, 2021 10.1038/s41401-020-00577-1
- Cells, 2021 10(3)532
- NPJ Breast Cancer, 2021 7(1):38
- J Virol, 2021 JVI0166621
- J Neurosci, 2021 JN-RM-0845-21
- Viruses, 2021 13(8)1533
- Biotechnol Bioeng, 2021 10.1002/bit.28016
- Sci Adv, 2021 7(35)eabb3799
- Mol Biomed, 2021 2(1):19
- J Clin Invest, 2020 130445
- Nucleic Acids Res, 2020 10.1093/nar/gkaa022
- Nucleic Acids Res, 2020 24;gkaa268
- Cancer Res, 2020 80(18):3841-3854
- EBioMedicine, 2020 59:102971
- Elife, 2020 9:e57894
- mBio, 2020 11(1)
- Commun Biol, 2020 3(1):378
- Biomolecules, 2020 13;10(5) pii: E761
- Oncotarget, 2020 11(37):3432-3442
- Mol Cancer Res, 2020 10.1158/1541-7786.MCR-19-0507
- J Biol Chem, 2020 295(1):125-137
- Nucleic Acids Res, 2019 47(18):9467-9479
- Nucleic Acids Res, 2019 47(16):8838-8859
- Cell Death Differ, 2019 10.1038/s41418-019-0393-7
- Cancer Res, 2019 79(1):99-113
- Proc Natl Acad Sci U S A, 2019 3;116(36):18021-18030
- Cancer Immunol Res, 2019 7(9):1523-1534
- Cell Death Dis, 2019 10(3):228
- Int J Cancer, 2019 144(1):98-109
- Oncogenesis, 2019 8(7):38
- Mol Cancer Ther, 2019 10.1158/1535-7163.MCT-19-0474
- J Neurosci, 2019 39(32):6378-6394
- Mol Cell Biol, 2019 39(24)e00181-19
- Cancers (Basel), 2019 11(12)
- Biosci Rep, 2019 39(9)
- Toxicol Sci, 2019 10.1093/toxsci/kfz178
- Mol Cells, 2019 42(3):210-217
- PLoS One, 2019 14(11):e0221288
- PLoS One, 2019 14(5):e0211090
- Nat Commun, 2018 9(1):764
- Nucleic Acids Res, 2018 46(10):5050-5060
- Nucleic Acids Res, 2018 46(17):8926-8939
- Nucleic Acids Res, 2018 46(10):5029-5049
- Clin Cancer Res, 2018 24(4):882-895
- Proc Natl Acad Sci U S A, 2018 115(2):E292-E301
- Cell Rep, 2018 24(13):3393-3403.e5
- JCI Insight, 2018 3(3)98096
- Front Immunol, 2018 9:2229
- Sci Signal, 2018 11(540)eaat0229
- Sci Rep, 2018 8(1):14421
- Sci Rep, 2018 8(1):14191
- Cell Cycle, 2018 17(17):2175-2186
- DNA Repair (Amst), 2018 68:12-24
- Exp Cell Res, 2018 366(1):24-33
- Sci Adv, 2018 4(12):eaat5077
- Mutat Res, 2018 808:20-27
- Autophagy, 2017 13(12):2056-2071
- Cell Rep, 2017 18(8):1970-1981
- Cell Rep, 2017 21(2):546-558
- Int J Mol Sci, 2017 18(4)
- Oncotarget, 2017 8(43):73925-73937
- Oncotarget, 2017 8(14):23492-23506
- Biochim Biophys Acta Mol Cell Res, 2017 1864(7):1195-1206
- J Cell Sci, 2017 130(6):1134-1146
- DNA Repair (Amst), 2017 54:30-39
- Med Sci Monit, 2017 23:4391-4400
- Nat Commun, 2016 7:13701
- Nucleic Acids Res, 2016 44(1):198-209
- Genes Dev, 2016 30(22):2500-2512
- Cancer Lett, 2016 383(1):41-52
- Cell Rep, 2016 16(8):2068-2076
- Front Plant Sci, 2016 7:1746
- Cell Cycle, 2016 15(4):546-58
- Int J Cancer, 2015 136(6):1445-57
- Int J Cancer, 2015 136(6):1445-57
- Oncotarget, 2015 6(25):21074-84
- Oncotarget, 2015 6(20):18094-104
- J Biol Chem, 2015 290(46):27473-86
- J Biol Chem, 2015 290(24):15030-41
- J Biol Chem, 2015 10.1074/jbc.M115.658419
- Cell Cycle, 2015 14(12):1908-24
- Biochem Biophys Res Commun, 2015 456(1):541-6
- Toxicol Sci, 2014 10.1093/toxsci/kfu207
- Oncol Lett, 2014 8(5):2043-2048
- Mol Cell Proteomics, 2013 12(10):2952-68
- Int J Cancer, 2013 135(2):479-91
- Biochem Pharmacol, 2013 86(12):1708-20
- Brain Pathol, 2012 22(5):677-88
化学信息&溶解度
分子量 | 547.67 |
分子式 | C30H33N3O5S |
CAS号 | 925701-49-1 |
Smiles | CC1CN(CC(O1)C)CC(=O)NC2=CC3=C(C=C2)SC4=C(C3)C=CC=C4C5=CC(=O)C=C(O5)N6CCOCC6 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 182.59 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 182.59 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 182.59 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:5mg/ml
(9.13mM)
操作示例:以 1 mL 工作液为例,取50μL100mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。